本页面由Tiger Trade Technology Pte. Ltd.提供服务

Ascendis Pharma A/S

218.10
-3.3900-1.53%
盘后218.100.00000.00%18:52 EST
成交量:168.44万
成交额:3.67亿
市值:134.56亿
市盈率:-48.06
高:222.99
开:211.00
低:211.00
收:221.49
52周最高:242.00
52周最低:118.03
股本:6,169.52万
流通股本:6,008.34万
量比:1.78
换手率:2.80%
股息:- -
股息率:- -
每股收益(TTM):-4.5384
每股收益(LYR):-6.7615
净资产收益率:-818.43%
总资产收益率:-7.69%
市净率:-65.16
市盈率(LYR):-32.26

数据加载中...

公司资料

公司名字:
Ascendis Pharma A/S
交易所:
NASDAQ
成立时间:
2006
员工人数:
1017
公司地址:
Tuborg Boulevard 12,Hellerup,Capital Region of Denmark,Denmark
邮编:
2900
传真:
- -
简介:
Ascendis Pharma A/s成立于2006年9月21日。该公司是一家临床阶段的生物制药公司,该公司运用其TransCon技术开发具有最佳的长效药物疗法的管道以解决大市场显著未满足的医疗需求。该公司正在开发其先导候选产品,TransCon人生长激素或生长激素TransCon,每周一次给药治疗生长激素缺乏症以及其他疾病。

董事

名称
职位
Albert Cha
Chairman of the Board and Director
Jan Moller Mikkelsen
Chief Executive Officer and Director and President
Lars Holtug
Director
Lisa Bright
Director
Siham Imani
Director
William Carl Fairey Jr.
Director

股东

名称
职位
Jan Moller Mikkelsen
Chief Executive Officer and Director and President
Mads Bodenhoff
Head of Finance and Principal Accounting Officer and Senior Vice President
Scott T. Smith
Executive Vice President, Chief Financial Officer
Aimee Shu
Executive Vice President, Chief Medical Officer
Flemming Steen Jensen
Executive Vice President, Product Supply and Quality
Jay Donovan Wu
Executive Vice President, U.S. President
Jethro Ekuta
Chief Regulatory & Safety Officer
Kennett Sprogøe
Executive Vice President, Head of Innovation and Research
Lotte Sonderbjerg
Executive Vice President, Chief Administrative Officer
Michael Wolff Jensen
Executive Vice President, Chief Legal Officer
Sherrie Glass
Chief Business Officer
Stina Singel
Executive Vice President, Head of Clinical Development, Oncology